Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cediranib + cilengitide
- Development stage
- Discontinued
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Cediranib + cilengitide is a combination therapy that was investigated for the treatment of recurrent glioblastoma. Cediranib is a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor that works by blocking blood flow to tumors. Cilengitide is an integrin inhibitor. The combination was designed to target both angiogenesis and tumor invasion pathways, as integrins are upregulated after VEGF inhibition and may play a role in resistance mechanisms to anti-VEGF therapy. Despite showing pharmacodynamic changes in blood and imaging biomarkers, the combination did not demonstrate sufficient survival and response rates to warrant further development.
- Other names
- C-National Cancer Institute (NCI)-glioblastomaCediranib Maleate + CilengitideCediranib and Cilengitide in Recurrent Glioblastoma
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFR (PDGFR family)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR2 (Vascular endothelial growth factor receptor 2)αVβ3 (Integrin αVβ3)VEGFR-1 (Vascular endothelial growth factor receptor 1)αVβ5 (Integrin αVβ5)
Beyond the preview
Go deeper on cediranib + cilengitide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cediranib + cilengitide.